| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Proposed share exchange transaction expected to create a multi-indication clinical stage company focused on targeting neutrophil extracellular traps (NETs) |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026 |
| 16 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
______________________________________________________________________________ |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition
Expanded collaborative research initiatives reinforce the Company's long-term |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Advancements across investigator-initiated studies, translational research and |
| 24 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Xenetic Biosciences, Inc. (the “Company”) hereby grants the following shares of restricted stock (“Restricted Stock”) pursuant to its Amended and Restated Equity Incentive Plan (as may be amended, the “Plan”). The terms of the grant are ... |
| 13 Mar 2026 |
8-K: Results of Operations and Financial Condition
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers |
| 09 Jan 2026 |
8-K: Other Events
On December 11, 2025, Xenetic Biosciences, Inc. (the “Company”) announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for December 11, 2025, had been adjourned until January 8, 2026 in order ... |
| 11 Dec 2025 |
8-K: Regulation FD Disclosure
FRAMINGHAM, MA – (December 11, 2025) – Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners |
| 14 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Xenetic Biosciences, Inc., a Nevada corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, 735,000 shar... |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Expanded strategic partnership with The Scripps Research Institute to advance |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Strategic focus on exploratory investigator-initiated clinical studies with institutional partners |
| 10 Apr 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by Xenetic Biosciences, Inc. under Item 4.01 of its Form 8-K. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Xene... |
| 19 Mar 2025 |
8-K: Results of Operations and Financial Condition
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers |
| 13 Dec 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On December 11, 2024, Xenetic Biosciences, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on the following four proposals and cast th... |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
– Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications |
| 07 Nov 2024 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Company is advancing DNase-based oncology program towards clinical |
| 31 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 14 Aug 2024 |
8-K: Results of Operations and Financial Condition
Ongoing preclinical studies with data expected before year end |
Loading...